deCODE falls from NASDAQ grace

The NASDAQ giveth and the NASDAQ taketh away, especially if you're a biotechnology company. While California-based linkurl:Celera Genomics;https://www.the-scientist.com/blog/display/55142/ made it onto the semi-annually updated NASDAQ Biotechnology Index (NBI), Iceland biotech linkurl:deCODE Genetics;https://www.the-scientist.com/blog/display/55089/ was booted off of the NBI after the company's stock price plunged this fall, linkurl:GenomeWeb;http://www.genomeweb.com/issues/news/150778-1.html?CMP

By | November 18, 2008

The NASDAQ giveth and the NASDAQ taketh away, especially if you're a biotechnology company. While California-based linkurl:Celera Genomics;https://www.the-scientist.com/blog/display/55142/ made it onto the semi-annually updated NASDAQ Biotechnology Index (NBI), Iceland biotech linkurl:deCODE Genetics;https://www.the-scientist.com/blog/display/55089/ was booted off of the NBI after the company's stock price plunged this fall, linkurl:GenomeWeb;http://www.genomeweb.com/issues/news/150778-1.html?CMP=OTC-RSS reported today (Nov. 18). NASDAQ ranks biotech companies in May and September every year. The rankings are based on several criteria, including having at least $100 million in market capitalization, an average daily trading volume of at least 50,000 shares, and a net worth of at least $5 million. The linkurl:current rankings;http://dynamic.nasdaq.com/dynamic/nasdaqbiotech_activity.stm list 145 companies, including heavy hitters linkurl:Amgen Inc.,;https://www.the-scientist.com/article/display/19256/ linkurl:Affymetrix Inc.;https://www.the-scientist.com/news/display/52891/ and linkurl:Invitrogen Corp.;https://www.the-scientist.com/blog/display/55183/ deCODE's stock price dropped to $0.54 last month - below the $1 threshold set for NASDAQ listing. The company was given 180 days to pull that figure up, but as yet has not. One share in deCODE was trading at $0.32 as of 1 PM Eastern time today. The new listing, with the addition of Celera and the omission of deCODE, will take effect when the market opens on November 24.

Popular Now

  1. 2017 Top 10 Innovations
    Features 2017 Top 10 Innovations

    From single-cell analysis to whole-genome sequencing, this year’s best new products shine on many levels.

  2. Thousands of Mutations Accumulate in the Human Brain Over a Lifetime
  3. Antiviral Immunotherapy Comes of Age
    News Analysis Antiviral Immunotherapy Comes of Age

    T-cell therapies are not just for cancer. Researchers are also advancing immunotherapy methods to protect bone marrow transplant patients from viral infections. 

  4. The Rising Research Profile of 23andMe
    News Analysis The Rising Research Profile of 23andMe

    An exploration of the genetics of earlobe attachment is just the latest collaborative research project to come out of the personal genetic testing company.

FreeShip